Anti-herpes simplex virus antibodies and methods of use thereof

1. An isolated human antibody that specifically binds to the glycoprotein D (gD) of herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2), wherein the antibody binds to a conformational epitope on the glycoprotein D and interacts with amino acids Y38, D215, P221, and R222 shown in SEQ ID NO:44 or SEQ ID NO:45 or amino acids on the gD corresponding to Y38, D215, P221, and R222 shown in SEQ ID NO:44 or SEQ ID NO:45.

2. The antibody of claim 1 , wherein the antibody interacts with amino acids 35-40 and 215-222 shown in SEQ ID NO:44 or SEQ ID NO:45 or amino acids on the gD corresponding to amino acids 35-40 and 215-222 shown in SEQ ID NO:44 or SEQ ID NO:45

3. The antibody of claim 1 , wherein the antibody inhibits reproduction of HSV-1 and/or HSV-2.

4. The antibody of claim 1 , wherein the antibody competes with antibody scFv E317, scFv E425, or scFv Y571 for binding to the gD of HSV-1 and HSV-2, and is able to neutralize HSV-1 and HSV-2 with substantially equivalent potency.

5. The antibody of claim 1 , wherein the antibody comprises a V H comprising the three complementarity determining regions (CDRs) of the V H of scFv E317 and a V L comprising the three CDRs of the V L of scFv E317.

6. The antibody of claim 5 , wherein the antibody comprises a V H comprising the amino acids 3-124 of SEQ ID NO:1 and/a V L comprising the amino acids 1-108 of SEQ ID NO:2.

7. The antibody of claim 5 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:5.

8. The antibody of claim 1 , wherein the antibody comprises a V H comprising the three CDRs of the V H of scFv E425 and a V L comprising the three CDRs of the V L of scFv E425.

9. The antibody of claim 8 , wherein the antibody comprises a V H comprising the amino acids 3-124 of SEQ ID NO:3 and a V L comprising the amino acids 1-108 of SEQ ID NO:4.

10. The antibody of claim 8 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:6.

11. The antibody of claim 1 , wherein the antibody comprises the three CDRs from the heavy chain amino acid sequence shown in SEQ ID NO:41, and the three CDRs from the light chain amino acid sequence shown in SEQ ID NO:42.

12. The antibody of claim 11 , wherein the antibody comprises the heavy chain amino acid sequence shown in SEQ ID NO:41, and the light chain amino acid sequence shown in SEQ ID NO:42.

13. The antibody of claim 11 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:43.

14. An isolated nucleic acid comprising a nucleotide sequence encoding the antibody of claim 1 .

15. A vector comprising the nucleic acid of claim 14 .

16. An isolated host cell comprising the nucleic acid of claim 14 .

17. A method of producing the antibody of claim 1 , comprising culturing a host cell that produces the antibody, and recovering the antibody from the cell culture.

18. A pharmaceutical composition comprising the antibody of claim 1 , and a pharmaceutically acceptable carrier.

19. An isolated nucleic acid comprising a nucleotide sequence encoding the antibody of claim 5 .

20. A vector comprising the nucleic acid of claim 19 .

21. An isolated host cell comprising the nucleic acid of claim 19 .

22. A method of producing the antibody of claim 5 , comprising culturing a host cell that produces the antibody, and recovering the antibody from the cell culture.

23. A pharmaceutical composition comprising the antibody of claim 5 , and a pharmaceutically acceptable carrier.

24. An isolated nucleic acid comprising a nucleotide sequence encoding the antibody of claim 6 .

25. A vector comprising the nucleic acid of claim 24 .

26. An isolated host cell comprising the nucleic acid of claim 24 .

27. A method of producing the antibody of claim 6 , comprising culturing a host cell that produces the antibody, and recovering the antibody from the cell culture.

28. A pharmaceutical composition comprising the antibody of claim 6 , and a pharmaceutically acceptable carrier.

29. An isolated nucleic acid comprising a nucleotide sequence encoding the antibody of claim 8 .

30. A vector comprising the nucleic acid of claim 29 .

31. An isolated host cell comprising the nucleic acid of claim 29 .

32. A method of producing the antibody of claim 8 , comprising culturing a host cell that produces the antibody, and recovering the antibody from the cell culture.

33. A pharmaceutical composition comprising the antibody of claim 8 , and a pharmaceutically acceptable carrier.

34. An isolated nucleic acid comprising a nucleotide sequence encoding the antibody of claim 9 .

35. A vector comprising the nucleic acid of claim 34 .

36. An isolated host cell comprising the nucleic acid of claim 34 .

37. A method of producing the antibody of claim 9 , comprising culturing a host cell that produces the antibody, and recovering the antibody from the cell culture.

38. A pharmaceutical composition comprising the antibody of claim 9 , and a pharmaceutically acceptable carrier.

39. An isolated nucleic acid comprising a nucleotide sequence encoding the antibody of claim 11 .

40. A vector comprising the nucleic acid of claim 39 .

41. An isolated host cell comprising the nucleic acid of claim 39 .

42. A method of producing the antibody of claim 11 , comprising culturing a host cell that produces the antibody, and recovering the antibody from the cell culture.

43. A pharmaceutical composition comprising the antibody of claim 11 , and a pharmaceutically acceptable carrier.

44. An isolated nucleic acid comprising a nucleotide sequence encoding the antibody of claim 12 .

45. A vector comprising the nucleic acid of claim 44 .

46. An isolated host cell comprising the nucleic acid of claim 44 .

47. A method of producing the antibody of claim 12 , comprising culturing a host cell that produces the antibody, and recovering the antibody from the cell culture.

48. A pharmaceutical composition comprising the antibody of claim 12 , and a pharmaceutically acceptable carrier.